Sargazi Nasrin, Takian Amirhossein, Daroudi Rajabali, Nahvijou Azin, Yaseri Mehdi, Ghanbari Motlagh Ali, Zendehdel Kazem
Department of Health Management, Policy and Economics, School of Public Health, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Department of Global Health and Public Policy, School of Public Health, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
J Prev (2022). 2022 Dec;43(6):841-857. doi: 10.1007/s10935-022-00697-w. Epub 2022 Aug 2.
Despite increasing global attention to the national human papillomavirus (HPV) immunization program, this program is controversial in Iran. Evidence indicates that HPV vaccination is not cost-effective in Iran. Using cost-effectiveness analysis for decision-making about public health interventions such as vaccination is controversial because its potential benefits may not fit this framework. This study aimed to evaluate the economic effects of the HPV vaccination by cost-benefit analysis (CBA) using bivalent and quadrivalent in Iran in 2020. We performed a CBA from a societal perspective. We used two approaches of the vaccine's economic benefits: willingness to pay by discrete choice experiment and cost of illness. Costs only included the vaccine cost. The cost of two doses of bivalent and quadrivalent vaccines were US $29 and the US $151, respectively (US $1 = IRR 42,000). The benefits of bivalent and quadrivalent vaccines were US $ - 432, US $380 per person using the willingness to pay approach, and they were US $7375 and US $6590 thorough cost-of-illness approach. The cost-benefit ratio (CBR) of bivalent and quadrivalent vaccines was - 15.11 and 2.51 by the willingness to pay approach, and 258.12 and 43.51 by the cost of illness approach. This study confirms the benefits of the national bivalent and quadrivalent vaccination programs and provides reliable evidence for policy-makers programming HPV vaccination.
尽管全球对国家人乳头瘤病毒（HPV）免疫计划的关注日益增加，但该计划在伊朗仍存在争议。有证据表明，HPV疫苗接种在伊朗并不具有成本效益。使用成本效益分析来为诸如疫苗接种等公共卫生干预措施做决策存在争议，因为其潜在益处可能不符合该框架。本研究旨在通过成本效益分析（CBA）评估2020年伊朗二价和四价HPV疫苗接种的经济影响。我们从社会角度进行了CBA。我们使用了两种疫苗经济效益的方法：离散选择实验的支付意愿和疾病成本。成本仅包括疫苗成本。两剂二价和四价疫苗的成本分别为29美元和151美元（1美元 = 42000伊朗里亚尔）。使用支付意愿方法，二价和四价疫苗的效益分别为每人 - 432美元和380美元，通过疾病成本方法则分别为7375美元和6590美元。通过支付意愿方法，二价和四价疫苗的成本效益比（CBR）分别为 - 15.11和2.51，通过疾病成本方法则分别为258.12和43.51。本研究证实了国家二价和四价疫苗接种计划的益处，并为政策制定者规划HPV疫苗接种提供了可靠证据。
